Chugai Pharmaceutical Co., Ltd. (4519.T) Stock
Chugai Pharmaceutical Co., Ltd.

Company profile
Chugai Pharmaceutical reported revenue of 1.26 trillion JPY for fiscal year 2025, up 7.5% from fiscal year 2024, and net income of 434.01 billion JPY. That is a net profit margin of 34.5% for fiscal year 2025. In Q3 2026 (the quarter ended September 30, 2026) revenue was 404.74 billion JPY, up 21.5% from a year before. Overseas was its largest region in fiscal year 2025, with 56% of revenue. In Q3 2026 it reported net income of 143.55 billion JPY, against net income of 111.21 billion JPY a year earlier. Our analysis of its filings shows revenue growing from 1.11 trillion JPY in fiscal year 2023 to 1.26 trillion JPY in fiscal year 2025, 6.4% a year on average. Chugai Pharmaceutical reports about 5,104 full-time employees.
What stands out
- Its net profit margin over the last four reported quarters was 35.6%, against a median of 14.4% for 5 listed companies of similar size in its industry.
- It was founded in 1925.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Largest shareholders
- Roche Holding AG59.89%
- Chugai Pharmaceutical Co., Ltd.1.98%
- Sumitomo Life Insurance Co.0.55%
- Tokio Marine Holdings, Inc.0.17%
- Sumitomo Mitsui Trust Asset Management Co., Ltd.0.07%
Share of the company, as of September 25, 2026
Leadership
- Osamu Okuda — President, CEO & Chairman, 62
- Iwaaki Taniguchi — Senior Executive Officer, CFO, Head of Finance & Director, 59
- Shinji Hidaka — Executive Vice President
- Tetsuya Yamaguchi — Executive Vice President
- Yoshiyuki Yano — Executive Vice President
How much revenue does Chugai Pharmaceutical make?
Chugai Pharmaceutical reported 1.26 trillion JPY in revenue for fiscal year 2025, up 7.5% from 1.17 trillion JPY in fiscal year 2024. In Q3 2026 revenue was 404.74 billion JPY.
Where does Chugai Pharmaceutical make most of its revenue?
Overseas: 56% of revenue by region in fiscal year 2025, followed by Japan (44%).
What companies are similar to Chugai Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Otsuka Holdings Co., Ltd. (4578.T), Daiichi Sankyo Company, Limited (4568.T), Astellas Pharma Inc. (4503.T), Eisai Co., Ltd. (4523.T).
How does Chugai Pharmaceutical's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Chugai Pharmaceutical, 35.6%; Otsuka Holdings Co., Ltd. (4578.T), 14.4%; Daiichi Sankyo Company, Limited (4568.T), 13.0%; Astellas Pharma Inc. (4503.T), 16.2%; Eisai Co., Ltd. (4523.T), 4.9%; Kyowa Kirin Co., Ltd. (4151.T), 16.2%.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Chugai Pharmaceutical Co., Ltd. (4519.T)”, data as of Sep 30, 2026, https://dataporium.tech/stocks/4519.T